LONDON, May 14, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), CTI BioPharma Corporation (NASDAQ: CTIC), StemCells Inc. (NASDAQ: STEM), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion%20Pharma&d=14-May-2015&s=ACHN. The US markets on Wednesday, May 13, 2015, ended on a mixed note as the Dow Jones Industrial Average finished at 18,060.49, down 0.04% and the NASDAQ Composite closed at 4,981.69, up 0.11%. The S&P 500 finished the session 0.03% lower at 2,098.48. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 843.82, down 0.02%, whereas the index has advanced 3.18% in the previous three months. Register for your complimentary reports at the links given below.
Achillion Pharmaceuticals Inc.'s stock fell 1.77%, to close the day at $9.45. The stock recorded a trading volume of 1.34 million shares, below its three months average volume of 3.49 million shares. The company's shares oscillated between $9.39 and $9.74 during the session. The stock has advanced 0.21% in the previous three trading sessions. However, over the last one month and over the past three months, Achillion Pharmaceuticals Inc.'s shares have lost 10.34% and 13.22%, respectively. The company is trading below its 50-day and 200-day moving averages. Achillion Pharmaceuticals Inc.'s 200-day moving average of $11.47 is above its 50-day moving average of $10.31. Additionally, the stock has a Relative Strength Index (RSI) of 46.52. Sign up and read the free notes on ACHN at:
On Wednesday, shares in CTI BioPharma Corp. recorded a trading volume of 1.90 million shares, lower than its three months average volume of 3.54 million shares. The stock ended the day at $1.75, which was 0.57% below its previous day's closing of $1.76, and registered an intraday range of $1.74 and $1.81. CTI BioPharma Corp.'s shares have lost 4.37% in the previous three trading sessions, 9.33% in the last one month, and 21.52% in the past three months. The company is trading below its 50-day and 200-day moving averages of $2.00 and $2.28, respectively. Furthermore, shares of CTI BioPharma Corp. have an RSI of 40.22. The complimentary notes on CTIC can be downloaded as in PDF format at:
StemCells Inc.'s stock lost 1.96% to end Wednesday's session at $0.62. The stock recorded a trading volume of 2.35 million shares, above its three months average volume of 1.33 million shares. The company's shares fluctuated between $0.62 and $0.66 during the session. StemCells Inc.'s shares have declined 33.97% since the beginning of 2015. Furthermore, the stock has plummeted 37.69% over the last one month and 43.12% in the previous three months. The company is trading below its 50-day and 200-day moving averages. StemCells Inc.'s 200-day moving average of $1.16 is above its 50-day moving average of $0.94. Additionally, the stock has an RSI of 29.10. Register for free on Investor-Edge and access the latest research on STEM at:
On Wednesday, shares in Progenics Pharmaceuticals Inc. fluctuated between $5.25 and $5.50 before ending the session 0.73% lower at $5.42. The stock reported a trading volume of 0.81 million shares, lower than its three months average volume of 0.95 million shares. Shares of the company traded at a PE ratio of 133.75. Progenics Pharmaceuticals Inc.'s stock has lost 3.04% in the previous three trading sessions, 13.42% in the last one month, and 4.24% in the past three months. The company is trading below its 50-day and 200-day moving averages of $6.06 and $5.86, respectively. Moreover, shares of Progenics Pharmaceuticals Inc. have an RSI of 44.96. The complete research on PGNX is available for free at:
Bluebird Bio Inc.'s stock finished Wednesday's session 3.53% lower at $160.34. A total of 0.94 million shares were traded, which was above its three months average volume of 0.69 million shares. The stock vacillated between $156.75 and $169.24 during the session. Over the last one month and over the past three months, Bluebird Bio Inc.'s shares have surged 24.66% and 76.78%, respectively. Additionally, from the beginning of 2015, the stock has surged 74.81%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $127.48 is greater than its 200-day moving average of $75.46. Bluebird Bio Inc.'s stock has an RSI of 79.10. Free in depth research on BLUE is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.